anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Hypertensive nephropathy (HN) is one of the main causes of end-stage renal disease (ESRD), leading to serious morbidity and mortality in hypertensive patients. However, existing treatment for hypertensive nephropathy are still very limited. It has been demonstrated that aerobic exercise has beneficial effects on the treatment of hypertension. However, the underlying mechanisms of exercise in HN remain unclear.
METHODS: The spontaneously hypertensive rats (SHR) were trained for 8 weeks on a treadmill with different exercise prescriptions. We detected the effects of moderate intensity continuous training (MICT) and high intensity interval training (HIIT) on inflammatory response, renal function, and renal fibrosis in SHR. We further investigated the relationship between TLR4 and the NLRC4 inflammasome in vitro HN model.
RESULTS: MICT improved renal fibrosis and renal injury, attenuating the inflammatory response by inhibiting TLR4/NF-κB pathway and the activation of NLRC4 inflammasome. However, these changes were not observed in the HIIT group. Additionally, repression of TLR4/NF-κB pathway by TAK-242 inhibited activation of NLRC4 inflammasome and alleviated the fibrosis in Ang II-induced HK-2 cells.
CONCLUSION: MICT ameliorated renal damage, inflammatory response, and renal fibrosis via repressing TLR4/NF-κB pathway and the activation of NLRC4 inflammasome. This study might provide new references for exercise prescriptions of hypertension.
Protein post-translational modifications (PTMs) are crucial for cancer cells to adapt to hypoxia; however, the functional significance of lysine crotonylation (Kcr) in hypoxia remains unclear. Herein we report a quantitative proteomics analysis of global crotonylome under normoxia and hypoxia, and demonstrate 128 Kcr site alterations across 101 proteins in MDA-MB231 cells. Specifically, we observe a significant decrease in K131cr, K156cr and K220cr of phosphoglycerate kinase 1 (PGK1) upon hypoxia. Enoyl-CoA hydratase 1 (ECHS1) is upregulated and interacts with PGK1, leading to the downregulation of PGK1 Kcr under hypoxia. Abolishment of PGK1 Kcr promotes glycolysis and suppresses mitochondrial pyruvate metabolism by activating pyruvate dehydrogenase kinase 1 (PDHK1). A low PGK1 K131cr level is correlated with malignancy and poor prognosis of breast cancer. Our findings show that PGK1 Kcr is a signal in coordinating glycolysis and the tricarboxylic acid (TCA) cycle and may serve as a diagnostic indicator for breast cancer.
OBJECTIVE: To develop a French Short Version of the Questionnaire of Olfactory Disorders-Negative Statements (Fr-sQOD) to assess the quality of life impairments of patients with olfactory dysfunction (OD).
METHODS: Patients with OD and controls were enrolled from 2 academic centers. Individuals completed the Fr-sQOD, an OD visual analog scale severity, and the French version of the sinonasal outcome tool-22 (SNOT-22). Cronbach α was used to measure the internal consistency of Fr-sQOD. The reliability and the external validity of Fr-sQOD were assessed through a test-retest approach and by correlating Fr-sQOD with SNOT-22 scores, respectively. The external validity was assessed by correlation analysis between Fr-sQOD and the result of an assessment of the severity of OD on a visual analog scale.
RESULTS: Eighty patients completed the evaluations. The internal consistency was adequate (Cronbach α .96), and the test-retest reliability was high in the entire cohort (rs = 0.877, P < .001). The correlation between Fr-sQOD total scores and the severity of OD was moderate but significant (rs = -0.431; P = .001) supporting an acceptable external validity. Patients with OD had a significantly higher score of Fr-sQOD than healthy individuals (P < .001), indicating a high internal validity.
CONCLUSION: The Fr-sQOD is a reliable and valid self-administered tool in the evaluation of the impact of OD on quality of life of French-speaking patients.
Compsns for the treatment of sunstroke and having a soothing action contain a suspension of acetylsalicylic acid (I). The compsns are applied externally to the affected parts. They do not cause side reactions e.g. in the liver, stomach or intestines, which occurs when a conventional medicament for sunstroke is taken internally. Further they do not have to be rubbed into the skin and so are painless to apply. Pref. the compsns. are aq. contain 3-10g (I) per litre. They may also contain a perfume, dye and an oil. In an example an aerosol contained 5g/litre (I) in distilled water, together with a perfume, colour, and an inert gas propellant.
The invention concerns a human cell differential transcriptional factor 14 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, infection of HIV, immunological diseases, and a variety of inflammation etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes a human cell differential transcription factor 14.
Cardiovascular status, especially of the patient with cardiac disease, should be carefully observed before and during transurethral resection of the prostate when using glycine irrigating solution, because the quantity of fluid absorbed into the systemic circulation by opened prostatic veins may produce significant expansion of the extracellular fluid and lead to fulminating congestive heart failure. Shift of sodium free intracellular fluid into the extracellular compartment following systemic absorption of solution may lower serum sodium concentration and aggravate pre-existing hyponatremia.

Care should be exercised if impaired liver function is known or suspected. Under such conditions, ammonia resulting from metabolism of glycine may accumulate in the blood.

Aseptic technique is essential with the use of sterile solutions for irrigation. The administration set should be attached promptly. Unused portions should be discarded and a fresh container of appropriate size used for the start-up of each cycle or repeat procedure.

Do not administer unless solution is clear, seal is intact and container is undamaged. Discard unused portion.
The present invention relates to a method for virus assay. More closely the invention relates a method for total quantification of adenovirus in a sample as well as total and functional (active) adenovirus in a sample. The method for determining adenovirus concentration in a sample comprises subjecting said sample to SPR (surface plasmon resonance) assay with immobilized FX (Factor X) and/or immobilized CAR (coxsackievirus and adenovirus receptor) on a sensor surface, wherein the adenovirus concentration is determined from sample binding to immobilized FX and/or immobilized CAR. CAR can be replaced by an ligand binding to adenovirus fiber, such as an anti-adenovirus fiber antibody. FX can be replaced by a ligand binding to adenovirus hexon, such as an anti-adenovirus hexon antibody. The method can be used for quality control in an adenovirus purification process, for example for gene therapy.
CardioCare Quest is a creative solution to addressing High Blood Pressure (HBP) and improving treatment compliance through a telehealth game, particularly among Navaho populations in Arizona. Integrating a telemetry system is a unique aspect that could offer valuable data on heart-healthy lifestyles in non-traditional clinical settings. The project's primary goals include designing and developing minigames combined with educational modules to enhance HBP treatment adherence and knowledge. Additionally, it seeks to collect preliminary data through a mixed-methods approach to evaluate the game's usability, engagement, and utility. This crucial step precedes the progression towards the R01 application for a comprehensive study evaluating the long-term effectiveness of the game. In Aim 1, the hypothesis is that the resulting affinity diagrams, which prioritize design problem statements, will enable them to share valuable insights on healthcare access disparities. This, in turn, provides crucial knowledge for developing targeted interventions to improve treatment compliance among Indigenous populations. In Aim 2, thematic analysis is applied to codesigned minigame prototypes using an emerging serious game theory. Aim 3 involves using a mixed methods approach to determine the impact of CardioCare Quest's telehealth interventions. The methodology of the CardioCare Quest project involves a participatory design approach that incorporates methods like bodystorming, brainstorming, and affinity diagramming that are tailored to the specific cultural and health needs of Indigenous populations in Arizona. This approach includes developing a series of engaging multiplayer minigames that focus on various aspects of HBP management, like diet, exercise, medication adherence, and lifestyle modifications.
PURPOSE: To obtain an oral hygiene composition containing a source of hydrogen citrate ions, an oxalate salt and an orally acceptable excipient, and having a caries-preventing action. CONSTITUTION: This oral hygiene composition contains 0.023-10wt.% of a source of hydrogen citrate ions (e.g. a hydrogen citrate salt), 0.0025-7wt.% of an oxalate salt and a conventional excipitent (additionally a surfactant, a gelling agent, a humectant, a flavor, a sweetener, a coloring agent). The composition preferably further contains an ionic fluorine-containing compound (e.g. sodium fluoride) in a fluoride ion/citric acid hydrogen ion weight ratio of 1:10 to 1:500, and is preferably controlled to a pH of 4-7. The composition may be prepared in the form of dentifrice or a mouthwash by conventional methods, and the components may be added to compositions for chewing gums, tablets, troches, etc.
The subjects will receive 6 weeks of the home exercise program via a smartphone application. The home exercise program sets the exercise intensity to 3 levels (low, medium, and high) according to the disease and consists of 2 stretches, 3 strengthening and/or functional exercises, and a cool-down exercise. The exercise group applies a daily home exercise program (30min/day, 7days/week for 6 weeks).
SOC is available to all young people in the delayed clusters. Care is provided in a nurse led Primary Health Clinics (PHC) to young people who attend the clinic. This includes HIV counselling and point of care testing, immediate initiation of ART if positive and PrEP if negative and eligible according to South African National PrEP guidelines. This is followed by a 3-monthly follow-up with repeat HIV testing, safety bloods, clinic-based counselling and adherence support and PrEP/ART refills. Clinic attendees are offered family planning support and syndromic management for STIs (as per South African National Department of Health Guideline).
Collagenase Santyl◊ Ointment should be applied once daily (or more frequently if the dressing becomes soiled, as from incontinence). When clinically indicated, crosshatching thick eschar with a #10 blade allows Collagenase Santyl◊ Ointment more surface contact with necrotic debris. It is also desirable to remove, with forceps and scissors, as much loosened detritus as can be done readily. Use Collagenase Santyl◊ Ointment in the following manner:

1 - Prior to application the wound should be cleansed of debris and digested material by gently rubbing with a gauze pad saturated with normal saline solution, or with the desired cleansing agent compatible with Collagenase Santyl◊ Ointment (See PRECAUTIONS ), followed by a normal saline solution rinse.

2 - Whenever infection is present, it is desirable to use an appropriate topical antibiotic powder. The antibiotic should be applied to the wound prior to the application of Collagenase Santyl◊ Ointment. Should the infection not respond, therapy with Collagenase Santyl◊ Ointment should be discontinued until remission of the infection.

3 - Collagenase Santyl◊ Ointment may be applied directly to the wound or to a sterile gauze pad which is then applied to the wound and properly secured.

4 - Use of Collagenase Santyl◊ Ointment should be terminated when debridement of necrotic tissue is complete and granulation tissue is well established.
PURPOSE: To provide an improved coating agent composed of an oblong elliptic solid drug coated with two coating layers, its production apparatus and production process. £ Lowering, lifting and holding means, coating tank, viscosity. CONSTITUTION: The product is most preferably held in a pair of parts aligned in axial direction in a collet. A plate is gradually introduced into a 1st immersion means and coated with a 1st coating substance. After the immersion, at least a part of the plate is turned 1.5 turns and the plate is introduced into the 2nd immersion means. Preferably, the plate is turned by a 2nd turning means to the original direction after the turn of 1.5 turns. The plate is transferred to a drying means for curing the 1st and the 2nd coatings to obtain a product coated each edge part with gelatin or other coating material.
In order to obtain enteric coated dosage forms and avoid using organic solution or aqueous dispersion of the enteric polymers, new formulations for solubilization of the enteric polymers in water have been developed. In these formulations, a buffering agent with high vapor pressure (eg ammonium hydrogen carbonate) is used to increase the pH of water to 7.8 (which resembles the pH of the intestinal fluid) and hence dissolves the enteric polymers. However, in these buffered systems the enteric polymers can be dissolved due to the ionization of the carboxyl groups. In contrast, upon drying the enteric coating, the components of the buffering agents evaporate (eg ammonium hydrogen carbonate decomposes to ammonia, carbon dioxide and water) and turn the polymers back to the non-ionized form. This in practice produces a film of enteric polymer at the surface of dosage forms. Using these formulations, a number of commercially available enteric polymers have been successfully applied to prepare enteric coated aspirin tablets by solution layering. Examples include cellulose acetate phthalate (CAP), hydroxy proply methyl cellulose acetate succinate (HPMCAS) and polymethracrylic acid ester. Hydroxy propyl methyl cellulose phthalate (HPMCP) coated tablets were found to have a rigid and dense property, which could not be achieved even by conventional organic solvent coatings.
Metformin hydrochloride 500mg XR tablets once daily by mouth for 2 weeks, escalating to a target dose of 1000mg XR once daily for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.
Contrast media are generally necessary for transcatheter left atrial appendage closure (LAAC), however, it should be avoided in patients with chronic kidney disease (CKD). The objective of this study was to evaluate the safety and feasibility of contrast-free LAAC with WATCHMAN FLX device for patients with CKD. Among 141 patients undergoing LAAC using the WATCHMAN FLX between May 2021 and March 2023, we performed LAAC without contrast media in 10 patients. Procedural and follow-up results were evaluated. The device size was selected based on the transesophageal echocardiographic (TEE) measurements. The device shape was assessed by fluoroscopy, and the device position was adjusted by TEE images. The mean age was 78 ± 4.9 years, CHADS2 score was 3.2 ± 1.1, and the estimated glomerular filtration rate (eGFR) was 28 ± 12 mL/min/1.73m2. The procedure was completed without contrast media in ten patients. Partial recapture of the device was required in four patients, but the initially selected device was finally implanted in all patients. Mean procedure time was significantly shorter in the contrast-free LAAC than in the contrast-use LAAC (41.6 ± 14.1 min vs 30.3 ± 7.6 min, p = 0.01). Postprocedural eGFR did not change from baseline, and there were no adverse events during the hospital stay. Follow-up TEE or cardiac computed tomography performed within 3 months after the procedure revealed no device-related thrombus or peri-device leak > 3 mm, and oral antithrombotic therapy was discontinued in all patients. Our experience shows that contrast-free LAAC using the WATCHMAN FLX device was safe and feasible. Non-contrast LAAC is one of the therapeutic options for patients with severe CKD.
Improved process for producing immunity sample is claimed in which a lipoid component is removed from an egg yolk and the resulting egg yolk is diluted and adjusted to a pH of 6 - 8 with a buffer agent and the diluted egg yolk solution is mixed with an aq. soluble mixt. consisting of a linear fibrous non-electrifying polymer and a precipitant and thereby, a non-dispersibility is imparted to an antibody of the egg yolk and then, the antibody having non-dispersibility is sepd. and collected from a produced supernatant solution. Above egg yolk is collected from an egg which is produced from an immunised hen having the antibody. Above linear fibrous non-electrifying polymer is chosen from nonyl-phenyl-ethoxylate, polyvinyl alcohol or polyvinyl-pyrrolidone and the precipitant is chosen from polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol - propylene glycol or dextran. Immunity sample is used for the transmission of passive immunity from maternal hen to chicken.
The invention discloses a composition for synergistically inhibiting pancreatic lipase and application thereof, and belongs to the technical field of natural medicines. The composition of the invention consists of isorhamnetin and a compound A; wherein, the compound A is selected from EGCG or luteolin. The composition can inhibit the activity of pancreatic lipase, thereby achieving the effect of preventing or treating obesity. There is a synergistic effect between the ingredients in the composition. The combined medication of the components can greatly reduce the dosage of the components when the components are independently used, and improves the inhibition activity of pancreatic lipase. Therefore, when the corresponding effect of preventing or treating obesity is achieved, the occurrence of drug resistance of the organism can be effectively reduced by using the low-dose combined drug.
We retrospectively reviewed patient charts of all patients admitted for shoulder dislocation at the ED at Copenhagen University Hospital Hvidovre between January 1st 2014 and December 31st 2014. A total of 151 patients' charts were reviewed.
For the first treatment, 250 mg/m2 Rituxan infusion and injection of IDEC-In2B8 (Indium- radioactive label) is given. If therapy is continued, approximately 1 week later a second infusion of Rituximab (250 mg/m2) is given followed by an infusion of IDEC-Y2B8 (Yttrium-radioactive label).
This invention relates to human medicine, and particularly with a pharmaceutical combination made up with Epidermal Growth Factor (EGF) and a Growth Hormone secretagogue hexapeptide (GHRP); being useful to prevent tissue damages due to blood flow suppression as to enhance tissue repair following ischaemic damages. The aforementioned combination may be applied as a single pharmaceutical composition. Alternatively, an individual may also receive both EGF and GHRP in a separate manner but within a single therapeutic regime to enhance cellular survival when organs are subjected to blood flow deprivation for a critical period of time. This combination attenuates reactive oxygen species (ROS) formation and its associated cytotoxicity. It is useful to promote cellular survival when tissues or organs are exposed to prolonged ischaemic periods. The combination may be used as a prophylactic agent in those subjects prone to multiple organ failure (MOF) such as burn victims, multiple trauma patients, hypoxic neonates, acute respiratory distress syndrome, and necrotizing enterocolitis patients.
BACKGROUND: Osteoarthritis (OA) is a common musculoskeletal disorder characterized by chondrocyte apoptosis and extracellular matrix degradation. This study aimed to investigate the role of CCL4/CCR5 in regulating chondrocyte apoptosis and reactive oxygen species (ROS) levels in OA progression.
METHODS: Bioinformatics analysis was employed to identify CCL4 as the target gene, following which primary chondrocytes were treated with varying concentrations of CCL4. Apoptosis rate of chondrocytes and ROS levels were assessed using flow cytometry. The mechanism by which CCL4 regulated the extracellular matrix was investigated through Western blot and Immunofluorescence analyses. Additionally, maraviroc, a CCR5 inhibitor, was administered to chondrocytes in order to explore the potential signaling pathway of CCL4/CCR5.
RESULTS: Our study found that CCL4 was predominantly up-regulated among the top 10 hub genes identified in RNA-sequencing analysis. Validation through quantitative polymerase chain reaction (qPCR) confirmed elevated CCL4 expression in patients with Hip joint osteoarthritis, knee joint osteoarthritis, and facet joint osteoarthritis. The upregulation of CCL4 was associated with an increase in chondrocyte apoptosis and ROS levels. Mechanistically, CCL4, upon binding to its receptor CCR5, triggered the downstream phosphorylation of P65 in the nuclear factor-κB (NF-κB) signaling pathway. In vitro experiments demonstrated that treatment with maraviroc mitigated chondrocyte apoptosis, reduced intracellular ROS levels, and attenuated extracellular matrix degradation.
CONCLUSION: The study highlights the critical role of CCL4/CCR5 in modulating chondrocyte apoptosis and ROS levels in OA progression. Targeting this pathway may offer promising therapeutic interventions for mitigating the pathogenic mechanisms associated with OA.
The invention discloses a saccharomyces cerevisiae expression long-acting recombinant elastin and application thereof in cosmetics, wherein the nucleotide sequence of the long-acting recombinant elastin is shown as Seq ID No. 1. The nucleotide sequence of the long-acting recombinant elastin is obtained by yeast codon optimization of an original sequence of natural elastin and is mainly obtained by artificial design of a key hexapeptide repetitive sequence GVGGAP. The long-acting recombinant elastin provided by the invention has good biocompatibility, antioxidant activity and reducing capacity. The long-acting recombinant elastin has advantages over elastin extracted from animal tissues and xenogenees in that it is soluble, free of viral hazards and low in rejection reactions. Compared with elastin extracted from animal tissues and variant, the long-acting recombinant elastin provided by the invention has the advantages of solubility, no virus hidden trouble and low rejection reaction.